FDA Launches Public List of Infant Formulas to Improve Transparency Under Operation Stork Speed

Details of the Update

The FDA has redesigned its online infant formula resources to improve accessibility and transparency for stakeholders. As part of this update, the agency introduced a centralized public listing of all infant formula products currently marketed in the United States. 

This listing includes both domestic and imported infant formula brands distributed in the U.S. and serves as a reference point for market visibility and regulatory oversight. Manufacturers are responsible for ensuring that the product information associated with their formulas remains accurate and up to date for inclusion in the public resource.

The initiative supports broader goals under Operation Stork Speed, which aims to improve the availability of regulatory information and strengthen resilience in the infant formula supply chain.

Effective Date

The enhanced infant formula web resources and the public product listing became effective on February 26, 2026.

Regulatory Impact

With the introduction of a public market listing, infant formula manufacturers distributing products in the United States are now subject to increased transparency expectations. All marketed formulas are publicly listed and may be subject to ongoing accuracy reviews. 

This heightened transparency may affect regulatory submissions, labeling considerations, and supply chain disclosures, as companies must ensure that publicly available product information aligns with regulatory filings and market activity.

Why It Matters

The update improves regulatory transparency and accessibility by providing a centralized source of information on infant formula products available in the U.S. market. By supporting digital access to regulatory and market data, the initiative also contributes to greater regulatory clarity, improved oversight, and more efficient information sharing among stakeholders, while maintaining a minimal administrative burden.

Who This Is Relevant For

This regulatory development is particularly relevant for infant formula manufacturers, regulatory affairs teams, quality assurance professionals, and commercial teams responsible for product listings, labeling accuracy, and market disclosures related to products distributed in the United States.

Next Steps

Stakeholders should review the updated FDA infant formula web resources and the newly published market list to ensure that internal records and public-facing product information are aligned.

Regulatory, quality, and commercial teams should verify that product listings and company information are accurately reflected in the public database. Organizations may also consider monitoring future transparency initiatives under Operation Stork Speed to remain informed about potential policy developments or regulatory actions.

As regulatory transparency initiatives continue to evolve, maintaining visibility into global regulatory updates becomes increasingly important. RegASK helps organizations monitor regulatory developments and manage compliance with workflows across multiple jurisdictions.

RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now. 

FAQs

What changes did the FDA introduce for infant formula resources in February 2026?

The FDA redesigned its online infant formula resources and launched a publicly accessible list of all infant formulas marketed in the United States to improve transparency and access to regulatory information.

What is Operation Stork Speed?

Operation Stork Speed is an initiative led by the FDA in collaboration with the Department of Health and Human Services (HHS) to strengthen transparency, safety, and supply resilience in the U.S. infant formula market.

Which products are included in the FDA’s new infant formula listing?

The public listing includes all infant formula products currently marketed in the United States, covering both domestic and imported brands distributed in the country.

How can RegASK help companies monitor regulatory updates related to infant formulas?

RegASK provides regulatory intelligence and workflow automation that enables organizations to track regulatory updates, monitor policy developments, and manage compliance requirements across global markets, helping teams stay aligned with evolving regulatory expectations.